-- ADDS COMMENT, DETAIL AND SHARE PRICE --
OptiBiotix Health (LON:OPTI) and Venture Life (LON:VLG) are teaming up to create products for the ageing population based around the former’s technology.
Venture will develop food supplements and over the counter products from existing OptiBiotix developments.
The pair will also look at new “microbiome actives” that target particular diseases that again will be turned into supplements or chemist-sold pills or powders.
The plan is then to market the new pipeline through Venture’s international network of distributors.
OptiBiotix chief executive Stephen O’Hara said: "The first item will be a weight-loss product which will be in the form of an over the counter presentation as a capsule or gelatin."
The two have signed a letter of intent ahead of sealing definitive legal and commercial terms.
OptiBiotix is creating a whole suite of potential blockbusters that harness and tweak the human microbiome to tackle obesity, diabetes and cholesterol.
Venture already has its own cholesterol lowering supplement and is marketing other products aimed at the developed world’s growing older generation.
O’Hara said: "Recent advances in OptiBiotix's technology platforms have broadened the range of product opportunities.
“We believe Venture Life's capabilities in formulating, manufacturing and distributing over-the-counter products through its network of international distributors creates potential to bring new products to new markets earlier than anticipated.”
The news follows last week's announcement that the company is in talks with a large cioroporate firm for its cholesterol lowering biome techology.
O'Hara said: "What we have tried to do over the last few months is find deals which do not overlap.
"We have a technology platform which allows us to make a whole range of products."
Shares eased 2.6% to 37.5p today on the announcement.